Opzelura and Disease recurrence - a phase IV clinical study of FDA data

Summary:

Disease recurrence is reported as a side effect among people who take Opzelura (ruxolitinib phosphate), especially for people who are have been taking the drug for < 1 month also take Xanax, and have Dermatitis atopic.

The phase IV clinical study analyzes which people have Disease recurrence when taking Opzelura. It is created by eHealthMe based on reports of 1,959 people who have side effects when taking Opzelura from the FDA, and is updated regularly.

What is Opzelura?

Opzelura has active ingredients of ruxolitinib phosphate. eHealthMe is studying from 1,961 Opzelura users. Check the latest studies of Opzelura.

What is Disease recurrence?

Disease recurrence is found to be associated with 1,244 drugs and 1,552 conditions by eHealthMe. Check the latest studies of Disease recurrence.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

1,959 people reported to have side effects when taking Opzelura.
Among them, 11 people (0.56%) have Disease recurrence.

Could Opzelura cause Disease recurrence?

Among these 11 people:

How long have people been on Opzelura when they have Disease recurrence? *

What are other drugs people take besides Opzelura? *

Xanax: 1 person, 9.09%

What are other side effects people have besides Disease recurrence? *

Acne (skin problems that cause pimples): 2 people, 18.18%
Tonsillar Hypertrophy (enlargement of the tonsils): 1 person, 9.09%
Swallowing Difficulty: 1 person, 9.09%
Rhinorrhea (watery mucus discharge from the nose): 1 person, 9.09%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 1 person, 9.09%
Headache (pain in head): 1 person, 9.09%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 1 person, 9.09%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 1 person, 9.09%

What are the existing conditions these people have? *

Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 4 people, 36.36%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 4 people, 36.36%
Vitiligo (pigment is lost from areas of the skin): 1 person, 9.09%
Skin Papilloma (a general medical term for a tumour of the skin or mucous membrane with finger-like projections): 1 person, 9.09%
Hand Dermatitis (hand infection of skin): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Opzelura and have Disease recurrence?

- Check whether Disease recurrence is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Opzelura:

Opzelura (1,961 reports)

Browse all side effects of Opzelura:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Disease recurrence:

Disease recurrence (1,244 drugs)

Browse all the conditions that are associated with Disease recurrence:

Disease recurrence (1,552 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ruxolitinib phosphate (the active ingredients of Opzelura) and Opzelura (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.